Related Experiment Video

Updated: Jun 29, 2025

Methyl-binding DNA capture Sequencing for Patient Tissues
08:40

Methyl-binding DNA capture Sequencing for Patient Tissues

Published on: October 31, 2016

8.6K

Landscape of m6A RNA methylation regulators in liver cancer and its therapeutic implications

Jindu Zhao1, Guo-Ying Li2, Xian-Ying Lu1

  • 1Department of Oncology Surgery, Anhui Medical University Children's Medical Center, Anhui Provincial Children's Hospital, Hefei, Anhui, China.

Frontiers in Pharmacology
|March 28, 2024
PubMed

Insights

N6-methyladenosine (m6A) RNA modification is crucial in liver cancer development. Targeting m6A regulators offers promising therapeutic strategies for advanced liver cancer, including hepatocellular carcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Liver cancer is a leading cause of cancer death globally.
  • Effective treatments for advanced liver cancer are limited, and its molecular mechanisms are not fully understood.
  • N6-methyladenosine (m6A) is a key RNA modification regulating RNA metabolism and is implicated in various cancers.

Purpose of the Study:

  • To review recent advancements in understanding the role of m6A regulators in liver cancer.
  • To elucidate the molecular mechanisms by which m6A influences liver cancer progression.
  • To explore the therapeutic potential of m6A-based inhibitors in liver cancer treatment.

Main Methods:

  • Literature review of recent research on m6A modification in liver cancer.
  • Analysis of studies investigating m6A regulators and their functions.
  • Examination of data on m6A-based therapeutic strategies.

Main Results:

  • m6A dysregulation is frequently observed in liver cancers such as hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and hepatoblastoma (HB).
  • m6A regulators impact critical cellular processes including RNA splicing, stability, and translation, thereby influencing liver cancer development.
  • Emerging evidence supports the therapeutic potential of targeting m6A pathways in liver cancer.

Conclusions:

  • m6A modification plays a significant role in the pathogenesis of liver cancer.
  • Understanding m6A regulatory networks is essential for developing novel liver cancer therapies.
  • m6A-based inhibitors represent a promising avenue for treating advanced liver cancer.
Keywords:
HBHCCICCN6-methyladenosine (m6A) modificationliver cancer

More Related Videos

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

10.0K
A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues08:56

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues

Published on: December 5, 2016

10.9K

Related Concept Videos

Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.0K
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.9K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K